Experimental data, from obese mouse models, suggests that mineralocorticoid receptor antagonists ameliorate obesity-associated vascular dysfunction, diastolic dysfunction, and HTN in female, but not male mice [27–29]. The gene discussed is NR3C2; the disease is obesity due to melanocortin 4 receptor deficiency.